XML 13 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation
9 Months Ended
Sep. 30, 2019
Share Based Compensation [Abstract]  
Share-Based Compensation

NOTE 6 – Share-Based Compensation

The table below sets forth the line items where share-based compensation expense was recorded:

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Cost of goods sold

$

281

 

 

$

96

 

 

$

665

 

 

$

267

 

Selling, general and administrative

 

4,566

 

 

 

3,993

 

 

 

12,513

 

 

 

13,477

 

Research and development

 

742

 

 

 

807

 

 

 

2,186

 

 

 

2,233

 

Total share-based compensation expense

$

5,589

 

 

$

4,896

 

 

$

15,364

 

 

$

15,977

 

 

The table below sets forth share-based compensation expense by type:

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Stock options

$

-

 

 

$

-

 

 

$

-

 

 

$

275

 

Share grants

 

5,589

 

 

 

4,896

 

 

 

15,364

 

 

 

15,702

 

Total share-based compensation expense

$

5,589

 

 

$

4,896

 

 

$

15,364

 

 

$

15,977

 

 

Stock Options. Approximately $7.2 million in cash proceeds was received from stock option exercises during the nine months ended September 30, 2019.

As of September 30, 2019, we had no unrecognized share-based compensation expense related to unvested stock options.  

Share Grants. Restricted stock awards and restricted stock units generally vest in equal annual installments over a four-year period.   We also have share grants that are performance-based and time-based that vest upon achievement of certain performance criteria over time.             

As of September 30, 2019, total unrecognized share-based compensation expense related to share grants was approximately $44.4 million, before income taxes, and is expected to be recognized over a weighted average period of approximately 2.3 years.